## OFFICE OF THE CITY MANAGER LITTLE ROCK, ARKANSAS

## BOARD OF DIRECTORS COMMUNICATION JANUARY 16, 2018 AGENDA

| Subject:   | Action Required:  | Approved By:                   |
|--|---|--------------------------------|
| Approval of a sole-source ordinance granting the City Manager the authority to enter into an agreement with GlaxoSmithKline (GSK) for a Vaccination Program for City Employees | √ <b>Ordinance</b> Resolution Approval Information Report   |                                |
| Submitted By:  |   | 5                              |
| Human Resources<br>Department  |   | Bruce T. Moore<br>City Manager |
| SYNOPSIS   | Approval of a sole-source ordinance authorizing the City Manager to use the Federal Center for Disease Control Program and Contract with GlaxoSmithKline (GSK) as a sole source to purchase vaccines needed to protect City employees from communicable diseases. The terms of the agreement are from February 1, 2018, to January 31, 2019, with the inclusion of the option to extend for four (4) additional years.  |                                |
| FISCAL IMPACT  | The amount is not to exceed \$40,000, and the funds required for this agreement are budgeted in the preventative medicine line item each year.  |                                |
| RECOMMENDATION   | Approval of the ordinance.  |                                |
| BACKGROUND   | Various groups of City employees are at risk for exposure to various communicable diseases, which are preventable by use of readily available vaccines. The current programs available vaccinate those employees against influenza, Hepatitis A and B, Rabies and several other conditions. The program offered by the Center for Disease Control (CDC) allows vaccines to be purchased directly from manufacturers at a lower cost than otherwise available. |                                |

## BACKGROUND CONTINUED

The City of Little Rock operates an aggressive program of vaccinating at risk employees against various communicable diseases. The CDC has negotiated arrangements for Governmental agencies to purchase vaccines directly from manufacturers at significantly lower cost than other arrangements.